Seres Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪137.01 M‬USD
−1.12USD
‪−250.16 M‬USD
‪7.13 M‬USD
‪97.76 M‬
Beta (1Y)
0.27

About Seres Therapeutics, Inc.

CEO
Eric D. Shaff
Headquarters
Cambridge
Employees (FY)
431
Founded
2010
ISIN
US81750R1023
FIGI
BBG0099X6859
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Forex, Futures, Bonds
4.5Great

See all brokers